- PsyBio Therapeutics Corp. (PSYB) has received approval from the United States Patent and Trademark Office for its latest non-provisional patent application
- The accepted patent application was submitted with information that was made up of advancements that support PsyBio’s novel production methodology
- The company is continuing to broaden its presence in the biosynthetic sector by developing psycho-targeted therapeutic candidates treating mental health issues
- PsyBio Therapeutics Corp. (PSYB) is up 6.25 per cent and is trading at $0.17 per share as of 3:19 p.m. ET
PsyBio Therapeutics (PSYB) has received approval from the United States Patent and Trademark Office for its latest non-provisional patent application.
The accepted patent application was submitted with information that was made up of advancements such as host strains and processes of production that support PsyBio’s novel production methodology.
Evan Levine, CEO of PsyBio, commented,
“With the formal acceptance of this patent application, PsyBio continues to demonstrate its leadership in the biosynthetic development field by prioritizing intellectual property protection, which is necessary for us to achieve our business objectives and potentially enhance shareholder value for our current and future investors.”
The company is continuing to broaden its presence in the biosynthetic sector by developing psycho-targeted therapeutic candidates to improve mental and neurological health.
Dr. Michael Spigarelli, PsyBio’s Chief Medical Officer, stated,
“This IP is the bedrock upon which the development of psycho-targeted molecules as novel therapeutic candidates is built… Our IP strategy fosters developmental processes and allows them to proceed as smoothly and rapidly as possible… [patent’s] ultimate acceptance further expands PsyBio’s intellectual property portfolio and supports ongoing plans for growth.”
PsyBio Therapeutics Corp. (PSYB) is up 6.25 per cent and is trading at $0.17 per share as of 3:19 p.m. ET.
